(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 97.53% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.61%.
Soleno Therapeutics's revenue in 2026 is $190,405,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $24,748,213,446, with the lowest SLNO revenue forecast at $21,937,781,981, and the highest SLNO revenue forecast at $28,121,866,940. On average, 12 Wall Street analysts forecast SLNO's revenue for 2027 to be $38,007,420,232, with the lowest SLNO revenue forecast at $31,660,202,220, and the highest SLNO revenue forecast at $47,700,930,816.
In 2028, SLNO is forecast to generate $52,347,125,376 in revenue, with the lowest revenue forecast at $39,208,719,648 and the highest revenue forecast at $60,142,407,360.